BR0312472A - Prepração de uma composição compreendendo uma mistura de complexos de iscom e uso da dita composição - Google Patents
Prepração de uma composição compreendendo uma mistura de complexos de iscom e uso da dita composiçãoInfo
- Publication number
- BR0312472A BR0312472A BR0312472-0A BR0312472A BR0312472A BR 0312472 A BR0312472 A BR 0312472A BR 0312472 A BR0312472 A BR 0312472A BR 0312472 A BR0312472 A BR 0312472A
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- iscom
- complexes
- mixture
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
"PREPARAçãO DE UMA COMPOSIçãO COMPREENDENDO UM MISTURA DE COMPLEXOS DE ISCOM E USO DA DITA COMPOSIçãO". A presente invenção se refere a uma composição compreendendo uma mistura de pelo menos dois complexos imunoestimuladores (daqui em diante referidos como ISCOM sigla em Inglês de 'Immunostimulating Complexes), cada complexo compreendendo substancialmente uma fração de saponina de Quillaja Saponaria Molina. Os complexos podem ser complexos de iscom ou complexos de matriz de iscom. A invenção também concerne o uso de tal mistura para a preparação de um produto farmacêutico imunomodulador e um coadjuvante, formulações para imunização, por exemplo, para produção de anticorpos monoclonais e uma vacina. De acordo com a invenção, também são incluídos kits de frações compreendendo pelo menos duas frações, em que cada fração compreende um complexo de iscom ou um complexo de matriz de iscom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202110A SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Iscom preparation and use thereof |
SE0202110-3 | 2002-07-05 | ||
PCT/SE2003/001180 WO2004004762A1 (en) | 2002-07-05 | 2003-07-07 | Iscom preparation and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0312472A true BR0312472A (pt) | 2005-04-26 |
BRPI0312472B1 BRPI0312472B1 (pt) | 2019-07-16 |
BRPI0312472B8 BRPI0312472B8 (pt) | 2021-05-25 |
Family
ID=20288449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0312472A BRPI0312472B8 (pt) | 2002-07-05 | 2003-07-07 | composição compreendendo dois complexos iscom diferentes |
Country Status (14)
Country | Link |
---|---|
US (3) | US20060121065A1 (pt) |
EP (1) | EP1539231B1 (pt) |
JP (1) | JP4636877B2 (pt) |
AT (1) | ATE434443T1 (pt) |
AU (1) | AU2003245220B2 (pt) |
BR (1) | BRPI0312472B8 (pt) |
CA (1) | CA2491457C (pt) |
DE (1) | DE60328108D1 (pt) |
DK (1) | DK1539231T3 (pt) |
ES (1) | ES2328474T3 (pt) |
NZ (1) | NZ537661A (pt) |
SE (1) | SE0202110D0 (pt) |
WO (1) | WO2004004762A1 (pt) |
ZA (1) | ZA200500073B (pt) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) * | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
PL1838341T3 (pl) | 2005-01-20 | 2014-04-30 | Isconova Ab | Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę |
EP1764369A1 (de) * | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
EP2004226A1 (en) | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Storage of influenza vaccines without refrigeration |
US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
EP1902727A1 (de) * | 2006-09-22 | 2008-03-26 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
WO2008031878A1 (en) * | 2006-09-15 | 2008-03-20 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases |
EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
WO2012011868A1 (en) * | 2010-07-23 | 2012-01-26 | Osterhaus A D M E | Influenza vaccine |
US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
ES2673957T5 (es) | 2011-10-03 | 2021-12-15 | Croda Int Plc | Nanopartículas, procedimiento para la preparación y utilización de las mismas como portadoras de moléculas anfipáticas o hidrofóbicas en el campo de la medicina, incluyendo el tratamiento del cáncer, y compuestos de tipo alimentario |
MX357009B (es) | 2011-11-28 | 2018-06-22 | Crucell Holland Bv | Vacunas contra el virus de la influenza y sus usos. |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
CN104379733B (zh) | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | 具改变末端的重组腺病毒群 |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
CA2900008A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
DK2863943T3 (en) | 2013-03-08 | 2016-11-07 | Janssen Vaccines & Prevention Bv | acellular pertussis vaccines |
AR095962A1 (es) | 2013-04-01 | 2015-11-25 | Moreinx Ab | Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos |
MX361774B (es) | 2013-04-25 | 2018-12-17 | Janssen Vaccines & Prevention Bv | Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados. |
CN105452270B (zh) | 2013-05-30 | 2020-12-01 | 扬森疫苗与预防公司 | 流行性感冒病毒疫苗及其用途 |
PE20160045A1 (es) | 2013-06-17 | 2016-02-18 | Crucell Holland Bv | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados |
EP3016679B1 (en) | 2013-07-02 | 2019-03-27 | Janssen Vaccines & Prevention B.V. | Method for preparing virosomes |
EP3017040B1 (en) | 2013-07-02 | 2018-06-06 | Janssen Vaccines & Prevention B.V. | Method for preparing virosomes |
KR101821712B1 (ko) | 2013-08-22 | 2018-01-24 | 주식회사 아데나 | 삼칠근 추출물, 비누풀잎 추출물, 검정콩 잎 추출물, 녹두 잎 추출물 및 호랑이콩 잎 추출물을 포함하는 Th2-매개 면역 질환 개선, 예방 또는 치료용 조성물 |
SG11201610443WA (en) | 2014-07-10 | 2017-01-27 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
CN107075521B (zh) | 2014-11-04 | 2021-06-08 | 扬森疫苗与预防公司 | 治疗性hpv16疫苗 |
US10570417B2 (en) | 2015-04-14 | 2020-02-25 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化された可溶性融合前rsv fポリペプチド |
WO2017005844A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
EA037295B1 (ru) | 2015-08-20 | 2021-03-05 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv18 |
US10538557B2 (en) | 2015-09-02 | 2020-01-21 | Janssen Vaccines & Prevention B.V. | Stabilized viral class I fusion proteins |
US10426829B2 (en) | 2015-09-03 | 2019-10-01 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
PE20181354A1 (es) | 2015-12-23 | 2018-08-22 | Pfizer | Mutantes de proteina f de rsv |
BR112018070323A2 (pt) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
AU2017259259B2 (en) | 2016-05-02 | 2020-11-19 | Bavarian Nordic A/S | Therapeutic HPV vaccine combinations |
RU2758238C2 (ru) | 2016-05-12 | 2021-10-26 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US11001858B2 (en) | 2016-06-20 | 2021-05-11 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
KR102111244B1 (ko) | 2017-02-09 | 2020-05-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 이종 유전자의 발현을 위한 강력한 짧은 프로모터 |
EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
EP3681533A1 (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
SG11202006399VA (en) | 2018-01-23 | 2020-08-28 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
KR20210004959A (ko) | 2018-03-19 | 2021-01-13 | 노바백스, 인코포레이티드 | 다가 인플루엔자 나노입자 백신 |
GB201807303D0 (en) | 2018-05-03 | 2018-06-20 | London School Of Hygeine & Tropical Medicine | Glyconjugate vaccines |
US20220111065A1 (en) | 2018-05-23 | 2022-04-14 | Adc Therapeutics Sa | Molecular adjuvant |
EP3880243A1 (en) | 2018-11-13 | 2021-09-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
MX2021012991A (es) | 2019-04-25 | 2021-12-10 | Janssen Vaccines & Prevention Bv | Antigenos de gripe recombinantes. |
CA3140234A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
US20220273787A1 (en) | 2019-05-15 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
CN114430742A (zh) | 2019-09-05 | 2022-05-03 | 扬森疫苗与预防公司 | 流感病毒疫苗及其用途 |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法-sars-cov-2ワクチン |
BR112022022942A2 (pt) | 2020-05-11 | 2022-12-13 | Janssen Pharmaceuticals Inc | Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada |
JP2023524860A (ja) | 2020-05-11 | 2023-06-13 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | SARS-CoV-2ワクチン |
KR20230009445A (ko) | 2020-05-11 | 2023-01-17 | 얀센 파마슈티칼즈, 인코포레이티드 | 안정화된 코로나바이러스 스파이크 단백질 융합 단백질 |
CA3188170A1 (en) | 2020-06-29 | 2022-01-06 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
EP4175971A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
JP2024511644A (ja) | 2021-04-01 | 2024-03-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前piv3 fタンパク質 |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
WO2023217988A1 (en) | 2022-05-12 | 2023-11-16 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
WO2024017682A1 (en) | 2022-07-18 | 2024-01-25 | Janssen Vaccines & Prevention B.V. | Rsv immunogens |
US20240042021A1 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
WO2024061753A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
WO2024104947A2 (en) | 2022-11-14 | 2024-05-23 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (sv) * | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
DK166762B1 (da) * | 1986-01-14 | 1993-07-12 | Nederlanden Staat | Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser |
US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) * | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
US6231859B1 (en) * | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
-
2002
- 2002-07-05 SE SE0202110A patent/SE0202110D0/xx unknown
-
2003
- 2003-07-07 ES ES03738849T patent/ES2328474T3/es not_active Expired - Lifetime
- 2003-07-07 BR BRPI0312472A patent/BRPI0312472B8/pt active IP Right Grant
- 2003-07-07 JP JP2004519469A patent/JP4636877B2/ja not_active Expired - Lifetime
- 2003-07-07 AT AT03738849T patent/ATE434443T1/de active
- 2003-07-07 EP EP03738849A patent/EP1539231B1/en not_active Expired - Lifetime
- 2003-07-07 US US10/520,022 patent/US20060121065A1/en not_active Abandoned
- 2003-07-07 WO PCT/SE2003/001180 patent/WO2004004762A1/en active Application Filing
- 2003-07-07 NZ NZ537661A patent/NZ537661A/en not_active IP Right Cessation
- 2003-07-07 DK DK03738849T patent/DK1539231T3/da active
- 2003-07-07 CA CA2491457A patent/CA2491457C/en not_active Expired - Lifetime
- 2003-07-07 DE DE60328108T patent/DE60328108D1/de not_active Expired - Lifetime
- 2003-07-07 AU AU2003245220A patent/AU2003245220B2/en not_active Expired
-
2005
- 2005-01-04 ZA ZA200500073A patent/ZA200500073B/xx unknown
-
2014
- 2014-12-31 US US14/587,116 patent/US10729764B2/en active Active
-
2020
- 2020-03-19 US US16/823,836 patent/US20200215189A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150209425A1 (en) | 2015-07-30 |
JP2006511451A (ja) | 2006-04-06 |
ES2328474T3 (es) | 2009-11-13 |
AU2003245220B2 (en) | 2009-04-23 |
US10729764B2 (en) | 2020-08-04 |
BRPI0312472B8 (pt) | 2021-05-25 |
US20200215189A1 (en) | 2020-07-09 |
BRPI0312472B1 (pt) | 2019-07-16 |
NZ537661A (en) | 2008-08-29 |
EP1539231A1 (en) | 2005-06-15 |
US20060121065A1 (en) | 2006-06-08 |
EP1539231B1 (en) | 2009-06-24 |
CA2491457C (en) | 2012-09-04 |
AU2003245220A1 (en) | 2004-01-23 |
SE0202110D0 (sv) | 2002-07-05 |
ZA200500073B (en) | 2006-02-22 |
DE60328108D1 (de) | 2009-08-06 |
DK1539231T3 (da) | 2009-09-14 |
ATE434443T1 (de) | 2009-07-15 |
CA2491457A1 (en) | 2004-01-15 |
JP4636877B2 (ja) | 2011-02-23 |
WO2004004762A1 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312472A (pt) | Prepração de uma composição compreendendo uma mistura de complexos de iscom e uso da dita composição | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
MY129263A (en) | Vaccine composition | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
ES2157447T3 (es) | Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio. | |
NO20082472L (no) | Vaksinesammensetninger omfattende en saponin adjuvant | |
WO2006113909A3 (en) | Humanized anti-cd70 binding agents and uses thereof | |
BRPI0609765A8 (pt) | mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano | |
NO20074392L (no) | Vaksine | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
MA29406B1 (fr) | Vaccin toxoide alpha de c. perfringens | |
WO2006033700A3 (en) | Her2 antibody composition | |
NO20031646L (no) | Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol | |
DK2054431T3 (da) | Konformere af bakterielle adhæsiner | |
BR0211761A (pt) | depsipeptìdeos e processos para preparar os mesmos | |
ATE389397T1 (de) | Adjuvante zusammensetzungen | |
DK1089968T3 (da) | Thyroideahormonanaloger og fremgangsmåder til deres fremstilling | |
BRPI0308606B8 (pt) | compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos | |
WO2022249106A3 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
WO2021158755A3 (en) | Leptospiral proteins and uses thereof | |
NO20090395L (no) | Farmasoytiske preparater inneholdende monoklonale antidiotype anti-CA-125-antistoff og aluminiumderivater | |
WO2023235660A3 (en) | Flavivirus immunogens and vaccine compositions and methods of using the same | |
AU6078399A (en) | Ligand presenting assembly (lpa), method of preparation and uses thereof | |
WO2004098529A3 (en) | Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 C/C 11, 8 C/C 13 E 25 DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |